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Lung Cancer Screening for the Poor and Underserved: 
Should Routine Screening be Performed?
Vaibhav Vermaa, d, Vladimir K. Gotlieba, Joshua Fogelb, Alan S. Multza, Geeti Sharmac
Abstract
Background: Lung cancer is a leading cause of death in United 
States. A recent study using low dose CT scans for screening long 
term smokers for lung cancer has, for the first time, demonstrated 
reduction in mortality, although it is not a standard of care in the 
community yet.
Methods: We analyzed lung cancer data for stages 0 through 4 for 
1,412 individuals from, a public hospital, Nassau University Medi-
cal Center (NUMC) with patients of lower income, two private hos-
pitals, North Shore University Hospital (NSUH) and Long Island 
Jewish Hospital (LIJ), with patients of higher income, with average 
household income per year of 83,795 $, 152,777 $ and 93,234 $ 
respectively.
Results: Significantly smaller percentages of patients were diag-
nosed with stages 0 and 1 lung cancer at NUMC (8.55%) versus 
either NSUH (36.18%, P < 0.001) or LIJ (35.70%, (P < 0.001).
Conclusions: At this point there is evidence that Lung Cancer 
Screening reduces mortality in long term smokers, but there is de-
bate over, if it should be made into a recommendation. In light of 
the above study we suggest, that screening for lower socioeconomic 
class, could be recommended, if not for general population.
Keywords: Lung cancer; Stage; Screening; Socioeconomic status
Introduction
Lung cancer is a leading cause of death in the United States, 
and it accounts for more deaths each year than breast, co-
lon and prostate cancer combined. Screening studies in the 
1980’s with chest x rays with or without cytological analysis 
of sputum did not show any impact on lung cancer specific 
mortality from screening high risk patients [1, 2]. Although a 
recent study using low dose CT scans of the chest in patients 
with higher risk factors for screening demonstrated reduc-
tion in mortality [3], this is not the current standard of care in 
the community. Based on current medical knowledge, only 
stage I lung cancer has successful cure numbers [4, 5], and a 
screening method capable of detecting these cases early may 
have a higher chance, of any method presently available, to 
be accepted as standard of practice.
We did a study to see if there is a significant difference 
in the stages of lung cancer at presentation diagnosed in 3 
different institutions of the same health system. Geographi-
cally located in a 15 mile radius, but represented by different 
racial, ethnic and socioeconomic groups, these institutions 
could represent a microcosm of lung cancer. Significant dif-
ferences would be interesting as it could shed light on cur-
rent standard practices, those who detect lung cancer earlier 
or practices that other hospitals are “not doing” and thereby 
detecting lung cancer later. This could lead to greater mortal-
ity and morbidity, because of presentation at later stages of 
the disease. This analysis could help identify the areas which 




We obtained retrospective data from 3 hospitals: Nassau 
University Medical Center-NUMC (years 2000 - 2009), 
Long Island Jewish Medical Center- LIJ (years 2007 - 2008) 
and North Shore University Hospital-NSUH (years 2007 - 
2008), which are parts of the same health system. We ob-
tained tumor registry summary data for frequency of total 
lung cancer diagnosed at different stages. The three hospitals 
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serve patients of different economic strata: NUMC patients 
have an average household income of $ 83,795 per year and 
average house cost of $ 385,610 and 27% minority popula-
tion; LIJ patients have an average household income of $ 
93,234 per year and average house cost of $ 481,700 and 
36% minority population; and NSUH patients have an aver-
age household income of $ 152,777 per year, average house 
cost of $ 999,390 and 20% minority population.
As appropriate, Pearson chi-square analyses were used 
to compare differences, unless there was a smaller sample 
Figure 1. Sample of Non Small Cell Cancers. Vertical axis: percentage of total patients diagnosed in various stages; Hori-
zontal axis: Stage of Lung Cancer; NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: 
Long Isiand Jewish Hospital; US: United States.





Stage 0-1 9.90% (10) 45.24% (176) 40.96% (77) < 0.001 < 0.001
Stage 2-3 24.75% (25) 20.57% (80) 28.19% (53)
Stage 4 65.35% (66) 34.19% (133) 30.85% (58)
Stage 0-1 9.90% (10) 45.24% (176) 40.96% (77) < 0.001 < 0.001
Stage 2-4 90.10% (91) 54.76% (213) 59.04% (111)
Stage 0-1 13.16% (10) 56.96% (176) 57.04% (77) < 0.001 < 0.001
Stage 4 86.84% (66) 43.04% (133) 42.96% (58)
Table 2. Sample of Those With Adenocarcinoma
NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.
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size for a cell of less than 5 and where the Fisher’s exact test 
was used. For the US national data (year 2006), the statisti-
cal assumption of independence was slightly relaxed as it is 
possible that these US data also included the individuals in 
the NUMC data. Our primary analysis was to compare the 
percentage for overall stage differences between the hospi-
tals for non-small cell cancer. Stata Version 11 was used for 
all analyses. All P-values were two sided. 
 
Results
The eligible sample of those with non-small cell lung can-
cer included 1,602 individuals. This included 401 individu-
als from NUMC with 66.83% (n = 268) below age 70 and 
33.17% (n = 133) age 70 and above; and 42.4% (n = 170) 
females and 57.6% (n = 231) males. There were 403 individ-
uals from LIJ with 46.65% (n = 188) below 70 years of age 
and 53.35% (n = 215) 70 years and above; and 50.62% (n = 
204) females, 49.38% and (n = 199) males. There were 798 
individuals from NSUH (North Shore University Hospital) 
with 48.62% (n = 388) below 70 years of age and 51.38% (n 
= 410) 70 years of age and above and 54.69% (n = 437) fe-
males, 45.31% and (n = 361) males. The sample sizes shown 
in the results section slightly differ for certain analyses due 
to omission of those with unknown or missing data.
Table 1 and Figure 1 show data for non-small cancers by 
stage. In the three-level analyses of stage groups of 0-1, 2-3, 
and 4, NUMC had an overall statistical significance for sepa-
rate comparisons to NSUH, LIJ, and the US national sample. 
These analyses showed much lower percentages of stage 0-1 
for NUMC as compared to the other sites, mixed results for 
stage 2-3 with higher percentages for NUMC as compared 
to NSUH and LIJ but lower than the US national sample 
and higher percentages for stage 4 as compared to NSUH, 
LIJ, and the US national sample. The stage 4 percentages 
for NUMC were at least 20% greater as compared to NSUH, 
LIJ, and the US national sample (Fig. 1).
In Table 1, two additional analyses were performed 
with only two-level analyses of stage groups.  One approach 
grouped stages 2-4 together and the other excluded stages 2-3 
from the analyses. In the analyses with stages 2-4 grouped 
together, NUMC had significantly lower percentages of 
stage 0-1 as compared to stages 2-4 for separate comparisons 
to NSUH, LIJ, and the US national sample. This ranged from 
18% lower for the US national sample and more than 25% 
lower than the NSUH and LIJ samples. In the analyses that 
excluded stages 2-3 from the analyses, NUMC had signifi-
Table 3. Sample of Those With Squamous Cell Carcinoma
NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United 
States. Note: Fisher’s exact test analyses used due to small sample size for NUMC.





Stage 0-1 7.14% (4) 37.88% (50) 39.33% (35) < 0.001 < 0.001
Stage 2-3 41.07% (23) 36.36% (48) 32.58% (29)
Stage 4 51.79% (29) 25.76% (34) 28.09% (25)
Stage 0-1 7.14% (4) 37.88% (50) 39.33% (35) < 0.001 < 0.001
Stage 2-4 92.86% (52) 62.12% (82) 60.67% (54)
Stage 0-1 12.12% (4) 59.52% (50) 58.33% (35) < 0.001 < 0.001
Stage 4 87.88% (29) 40.48% (34) 41.67% (25)
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cantly greater percentages of those with stage 4 as compared 
to stages 0-1 for separate comparisons to NSUH, LIJ, and the 
US national sample. This was more than 25% greater than 
the US national sample and more than 35% greater than the 
NSUH and LIJ samples.
Table 2 shows data for adenocarcinoma by stage. In the 
three-level analyses of stage groups of 0-1, 2-3, and 4, NUMC 
had an overall statistical significance for separate compari-
sons to NSUH and LIJ. These analyses showed much lower 
percentages of stage 0-1 for NUMC as compared to NSUH 
and LIJ, mixed results for stage 2-3 with higher percentages 
for NUMC as compared to NSUH but lower than LIJ and 
higher percentages for stage 4 as compared to NSUH and 
LIJ. The stage 4 percentages for NUMC were at least 30% 
greater as compared to the NSUH and LIJ samples.
In Table 2, two additional analyses were performed 
with only two-level analyses of stage groups. One approach 
grouped stages 2-4 together and the other excluded stages 2-3 
from the analyses. In the analyses with stages 2-4 grouped 
together, NUMC had significantly lower percentages of 
stage 0-1 as compared to stages 2-4 for separate compari-
sons to NSUH and LIJ. This was at least 30% lower than the 
NSUH and LIJ samples. In the analyses that excluded stages 
2-3 from the analyses, NUMC had significantly greater per-
centages of those with stage 4 as compared to stages 0-1 for 
separate comparisons to NSUH and LIJ. This was more than 
40% greater than the NSUH and LIJ samples.
Table 3 shows data for squamous cell carcinoma by 
stage. In the three-level analyses of stage groups of 0-1, 2-3, 
and 4, NUMC had an overall statistical significance for sepa-
rate comparisons to NSUH and LIJ. These analyses showed 
much lower percentages of stage 0-1 for NUMC as compared 
to the other sites, higher percentages for stage 2-3 for NUMC 
as compared to NSUH and LIJ, and higher percentages for 
stage 4 as compared to NSUH and LIJ. The stage 4 percent-
ages for NUMC were at least 20% greater as compared to 
NSUH and LIJ.
In Table 3, two additional analyses were performed 
with only two-level analyses of stage groups. One approach 
grouped stages 2-4 together and the other excluded stages 2-3 
from the analyses. In the analyses with stages 2-4 grouped 
together, NUMC had significantly lower percentages of 
stage 0-1 as compared to stages 2-4 for separate compari-
sons to NSUH and LIJ. This was at least 30% lower than the 
NSUH and LIJ samples. In the analyses that excluded stages 
2-3 from the analyses, NUMC had significantly greater per-
centages of those with stage 4 as compared to stages 0-1 for 
separate comparisons to NSUH and LIJ. This was more than 
45% greater than the NSUH and LIJ samples.
Discussion
  
We found significant differences for lung cancer where 
NUMC had greater percentages of stage 4 lung cancer and 
lower percentages of stages 0-1 lung cancer as compared to 
the two other local hospitals within the same health care sys-
tem and the US national data. This was seen in non-small 
cell cancers as well as adenocarcinoma and squamous cell 
carcinoma. This is in contrast to an earlier study done in 
Canada which did not show significant difference in stage at 
diagnosis in different socioeconomic groups [6]. Apart from 
this, there are multiple studies assessing impact of socioeco-
nomic status generally on survival of cancer patients [7, 8]
Also, those at NUMC who were diagnosed with lung 
cancer were relatively younger. This finding was indepen-
dent of histology. We did not have enough numbers of ad-
enosquamous, large cell carcinoma, carcinoid, and sarcoma-
toid cancers so we did not compare data for these cancers.
One of the most significant findings of this study was 
that significantly less people with lung cancer were being 
diagnosed in stage 1 at NUMC which caters to lower so-
cioeconomic patients and a larger minority population as 
compared to NSUH and LIJ which caters to predominantly 
a more affluent section of the population and lesser minority 
population. This has a very significant bearing on the mortal-
ity that lung cancer leads to as for practical purpose stages 
0-1 are the only curable stage of lung cancer [5, 6]. This is 
unfortunate, since despite appropriate diagnostic modali-
ties considerable number of patients become fatal victims of 
lung cancer because they are financially disadvantaged and 
therefore may not come in contact with the health system as 
frequently as they should.
This finding is very relevant in light of the recent study, 
demonstrating reduction of mortality of lung cancer by low 
dose CT scan for the first time in 30 years [3]. This has not 
been made into a formal recommendation yet as debate is 
going on, considering the costs the health care system would 
incur to recommend CT scan for screening purpose and pos-
sible radiation concerns from CT scans. In view of above 
findings we want to suggest that screening for lung cancer 
in people of lower socioeconomic classes or minorities may 
be useful. This topic should be considered as part of a risk-
benefit analysis about screening benefits versus CT dose ra-
diation long term side effects.
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